What’s new with the shingles vaccine

Shingrix offers more protection than its predecessor.

Image: © Zerbor/Thinkstock

A new vaccine to protect against shingles could offer almost double the protection for older adults compared with the one currently in use.

The original shingles vaccine, Zostavax, which was issued in 2006, reduces the risk of shingles by an average of 51%, but it becomes less effective as people age. It has a success rate of 70% for people ages 55 to 59, but that drops to 64% for those in their 60s, 41% for those in their 70s, and only 18% for those ages 80 and older.

To continue reading this article, you must login.
  • Research health conditions
  • Check your symptoms
  • Prepare for a doctor's visit or test
  • Find the best treatments and procedures for you
  • Explore options for better nutrition and exercise
Learn more about the many benefits and features of joining Harvard Health Online »